Q4 2022 revenues grew 643% year-over-year to $4.2 million Q4 2022 gross margin grew to 31.5%, generated $1.3 million of gross profit Completed acquisition of Novamind, positioning Numinus as a leading, integrated mental healthcare company providing psychedelic-assisted therapies Ended quarter with cash position of $33.0 million All financial results are reported in Canadian dollars unless…

Source

Previous articlePsyBio Therapeutics Announces Non-Brokered Private Placement Financing
Next articlePsychedelics Weekly – Cannabis as an Adjunct Cancer Treatment & 5-MeO-DMT Reactivations